The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
Haigh, Joseph Edward (The Christie NHS Foundation Trust (Manchester, Regne Unit))
Patel, Karan (The Christie NHS Foundation Trust (Manchester, Regne Unit))
Rack, Sam (The Christie NHS Foundation Trust (Manchester, Regne Unit))
Jiménez-Labaig, Pablo (Universitat Autònoma de Barcelona. Departament de Medicina)
Betts, Guy (Manchester University NHS Foundation Trust)
Harrington, Kevin Joseph (The Institute of Cancer Research)
Metcalf, Robert (The Christie NHS Foundation Trust (Manchester, Regne Unit))

Data:	2024
Resum:	Salivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2, and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on the efficacy of HER2-directed therapies in SGC. This is a retrospective observational study using anonymised data from commercial compassionate-use access registrations and a privately funded pharmacy prescribing register. Treatment duration was defined as the time from drug initiation to treatment discontinuation. Kaplan-Meier analysis of treatment duration was performed using R for Windows (v4. 3. 2). A case report is also provided of an exceptional responder. Eighteen patients were identified who received HER2-directed therapies for HER2-positive recurrent/metastatic SGC, and complete data on treatment duration was available for 15/18. Histology was salivary duct carcinoma in 13/18 patients, adenocarcinoma NOS in 4/18, and carcinoma ex pleomorphic adenoma in 1/18. The median treatment duration was 8. 3 months (95% CI: 6. 41-not reached), and the range was 1. 0-47. 0 months. Choice of HER2-directed therapy varied, with ado-trastuzumab emtasine being the most common (9/18). At the time of analysis, HER2-directed therapy was ongoing for 9/15, discontinued due to disease progression for 4/15, discontinued due to toxicity for 1/15, and 1/15 was discontinued for an unspecified reason. An exceptional responder experienced a complete response with a treatment duration of 47. 0 months. These real-world data are comparable to the median PFS observed with HER2-directed therapies in phase II trials and support the use of HER2-directed therapies in this group.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Salivary gland cancer ; HER2 ; Trastuzumab ; TDM1 ; Ado-trastuzumab emtansine ; Trastuzumab deruxtecan
Publicat a:	Current Oncology, Vol. 31 (september 2024) , p. 5652-5661, ISSN 1718-7729

DOI: 10.3390/curroncol31090419
PMID: 39330047

10 p, 1.2 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats